Genキュrix has been selected as a co-research and development institution for a national project to develop a next-generation digital PCR platform for the early detection of major cancers.

According to a disclosure on the 16th, Genキュrix will jointly conduct the 'Development of a Next-Generation Digital PCR Integrated Platform for Early Detection of Major Cancers' project, which is part of the 'First New Support Project for Advanced Medical Device R&D in 2026' organized by the Inter-Ministry Medical Device R&D Project Group.

• ■ KRW 29.38 Billion Project... Genキュrix Secures KRW 4 Billion in Government Funding
• The total project cost for this national initiative amounts to KRW 29,383,741,000. Genキュrix's share is KRW 5,333,335,000, with the detailed funding breakdown as follows:
• Government funding: KRW 4 billion
• Private contribution (cash): KRW 133,335,000
• Private contribution (in-kind): KRW 1.2 billion

The secured government funding of KRW 4 billion accounts for 15.9% of Genキュrix's equity capital (KRW 25,154,598,470). The project will run for approximately 6 years and 9 months, from April 1, 2026, to December 31, 2032. The date of occurrence, decision date, and contract date are all specified as June 16, 2026, in the disclosure.

■ Leading Development of Early Diagnosis Kits for Gastrointestinal Cancers... Targeting MFDS Approval The core of this project is to develop next-generation equipment for early detection of major cancers using digital PCR technology. The ultimate goal is to obtain at least one domestic Ministry of Food and Drug Safety (MFDS) certification or approval for in vitro diagnostic medical devices, or one or more overseas approvals for the final R&D products.

During the project period, Genキュrix will be responsible for developing prototypes and conducting performance evaluations of early diagnosis kits for gastrointestinal cancers, including liver, colorectal, and stomach cancers. In particular, the liver cancer early diagnosis kit will undergo confirmatory clinical trials for approval, with the goal of obtaining MFDS approval as research and development continues.